Manish Bhandari, MD
Medical Oncology · Edgewood, KYNPI 1356337430
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,267 of the $1,437 with a category attached, or 88.2%. It is spread thinly across 26 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $943 and has fallen 94.8% since, to $49 in 2025. That places this record below the midpoint for medical oncology clinicians in KY, where the typical reported total is $3,396.
Across 82 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$190
- Johnson & Johnson$147
- Pfizer$135
- AstraZeneca$110
- AbbVie$108
- Eisai Inc.$103
- plus $642 from 20 others
Across 9 payments — averaging $5482.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$35K
- Puma Biotechnology, Inc.$8K
- F. Hoffmann-la Roche AG$5K
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Food & beverage$1,26788%
- Education$17012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $190 |
| Johnson & Johnson(2 entities) | 11 | $147 |
| Pfizer | 15 | $135 |
| AstraZeneca | 2 | $110 |
| AbbVie | 2 | $108 |
| Eisai Inc. | 6 | $103 |
| Astellas Pharma US Inc | 5 | $85 |
| E.r. Squibb & Sons, L.L.C. | 6 | $83 |
| Incyte Corporation | 1 | $61 |
| Merck | 4 | $53 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $50 |
| Lilly USA, LLC | 3 | $49 |
| Agios Pharmaceuticals, Inc. | 1 | $43 |
| Foundation Medicine, Inc. | 1 | $39 |
| Genentech USA, Inc. | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| Bayer | 1 | $13 |
| Dendreon Pharmaceuticals LLC | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Lexicon Pharmaceuticals, Inc. | 1 | $12 |
| Exelixis Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$1,437 in reported general payments places this provider in the 40th percentile of 53 medical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 32 | $563,836 |
| JakafiRuxolitinib Phosphate | 26 | $448,951 |
| PomalystPomalidomide | 19 | $439,665 |
| CalquenceAcalabrutinib Maleate | 25 | $376,552 |
| ImbruvicaIbrutinib | 18 | $291,979 |
| PemazyrePemigatinib | 15 | $282,850 |
| BrukinsaZanubrutinib | 15 | $225,502 |
| ErleadaApalutamide | 13 | $189,369 |
| IbrancePalbociclib | 11 | $173,730 |
| TafinlarDabrafenib Mesylate | 12 | $154,599 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $147,953 |
| VerzenioAbemaciclib | 11 | $126,303 |
| EliquisApixaban | 39 | $24,150 |
| Fondaparinux Sodium | 12 | $23,890 |
| Abiraterone Acetate | 14 | $21,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi, Pemazyre | $61 | $731,80041 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $83 | $439,66519 claims |
| AstraZenecaCalquence | $110 | $376,55225 claims |
| NovartisTafinlar, Mekinist | $190 | $302,55224 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $50 | $291,97918 claims |
| PfizerIbrance, Eliquis | $135 | $197,88150 claims |
| Johnson & JohnsonErleada | $147 | $189,36913 claims |
| Lilly USA, LLCVerzenio | $49 | $126,30311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 53 medical oncology providers in Kentucky.
Other medical oncology in Edgewood
- Minsig ChoiEdgewood$348K
- Matthew KurianEdgewood$47K
- Douglas FloraEdgewood$20K
- Lawrence BrennanEdgewood$3K
- Mary Redden BorowskiEdgewood$675
- Christy SappEdgewood$466
- David MoskoEdgewood$223
- William DannemanEdgewood$47
- Lowell AnthonyLexington$55K
- Jewraj MaheshwariOwensboro$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.